Mutations in the sonic hedgehog pathway cause macrocephaly-associated conditions due to crosstalk to the PI3K/AKT/mTOR pathway

被引:21
|
作者
Klein, Steven D. [1 ]
Nguyen, Dzung C. [1 ]
Bhakta, Viraj [1 ]
Wong, Derek [2 ]
Chang, Vivian Y. [3 ,4 ]
Davidson, Tom B. [3 ,4 ]
Martinez-Agosto, Julian A. [1 ,2 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Med Genet, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Hematol Oncol, Los Angeles, CA 90095 USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA
关键词
SIGNALING PATHWAY; DUPLICATION; ACTIVATION; TARGET; NOTCH; GLI1;
D O I
10.1002/ajmg.a.61368
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The hedgehog (Hh) pathway is highly conserved and required for embryonic patterning and determination. Mutations in the Hh pathway are observed in sporadic tumors as well as under syndromic conditions. Common to these syndromes are the findings of polydactyly/syndactyly and brain overgrowth. The latter is also a finding most commonly observed in the cases of mutations in the PI3K/AKT/mTOR pathway. We have identified novel Hh pathway mutations and structural copy number variations in individuals with somatic overgrowth, macrocephaly, dysmorphic facial features, and developmental delay, which phenotypically closely resemble patients with phosphatase and tensin homolog (PTEN) mutations. We hypothesized that brain overgrowth and phenotypic overlap with syndromic overgrowth syndromes in these cases may be due to crosstalk between the Hh and PI3K/AKT/mTOR pathways. To test this, we modeled disease-associated variants by generating PTCH1 and Suppressor of Fused (SUFU) heterozygote cell lines using the CRISPR/Cas9 system. These cells demonstrate activation of PI3K signaling and increased phosphorylation of its downstream target p4EBP1 as well as a distinct cellular phenotype. To further investigate the mechanism underlying this crosstalk, we treated human neural stem cells with sonic hedgehog (SHH) ligand and performed transcriptional analysis of components of the mTOR pathway. These studies identified decreased expression of a set of mTOR negative regulators, leading to its activation. We conclude that there is a significant crosstalk between the SHH and PI3K/AKT/mTOR. We propose that this crosstalk is responsible for why mutations in PTCH1 and SUFU lead to macrocephaly phenotypes similar to those observed in PTEN hamartoma and other overgrowth syndromes associated with mutations in PI3K/AKT/mTOR pathway genes.
引用
收藏
页码:2517 / 2531
页数:15
相关论文
共 50 条
  • [21] Stability Analysis of the PI3K–Akt–mTOR Signaling Pathway
    Sapega T.S.
    Guria G.T.
    Biophysics, 2020, 65 (2) : 259 - 267
  • [22] The PI3K/Akt/mTOR Pathway as Therapeutic Target in Neuroblastoma
    Fulda, S.
    CURRENT CANCER DRUG TARGETS, 2009, 9 (06) : 729 - 737
  • [23] Targeting the mTOR/AKT/PI3K pathway in paediatric malignancies
    Pearson, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S74 - S74
  • [24] AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
    Bhatt, Aadra P.
    Damania, Blossom
    FRONTIERS IN IMMUNOLOGY, 2013, 3
  • [25] Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
    Zhou, Qian
    Lui, Vivian W. Y.
    Yeo, Winnie
    FUTURE ONCOLOGY, 2011, 7 (10) : 1149 - 1167
  • [26] Targeting the PI3K/AKT/mTOR Signaling Pathway in Medulloblastoma
    Dimitrova, V.
    Arcaro, A.
    CURRENT MOLECULAR MEDICINE, 2015, 15 (01) : 82 - 93
  • [27] Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
    Sun, Eun Jin
    Wankell, Miriam
    Palamuthusingam, Pranavan
    McFarlane, Craig
    Hebbard, Lionel
    BIOMEDICINES, 2021, 9 (11)
  • [28] PI3K/AKT/mTOR pathway in tumor progression of oligodendrogliomas
    Lisi, Lucia
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (04) : 2161 - 2163
  • [29] PI3K/Akt/mTOR pathway as a target for cancer therapy
    Morgensztern, D
    McLeod, HL
    ANTI-CANCER DRUGS, 2005, 16 (08) : 797 - 803
  • [30] PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours
    Zhang, Zixuan
    Wang, Mengzhao
    ONCOLOGY LETTERS, 2017, 14 (02) : 1373 - 1378